<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:  Point of Care Metabolic Measurement</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>08/01/2021</AwardEffectiveDate>
<AwardExpirationDate>07/31/2023</AwardExpirationDate>
<AwardTotalIntnAmount>999101.00</AwardTotalIntnAmount>
<AwardAmount>999101</AwardAmount>
<AwardInstrument>
<Value>Cooperative Agreement</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Henry Ahn</SignBlockName>
<PO_EMAI>hahn@nsf.gov</PO_EMAI>
<PO_PHON>7032927069</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be to improve diagnosis of specific disorders with metabolic measurement of whole blood.  It will be used at the point of care as a rapid diagnostic for newborn screening (~3.9 million babies born annually in the U.S.) and as a daily monitoring system for people living with specific diseases (~600,000 people in the U.S.). This will improve clinical outcomes at reduced cost of care.&lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase II project will address specific technical challenges in the device design to increase the signal-to-noise ratio, expected to increase by a factor of 10.  The systems engineering and quality control will also be explored to prepare for translation at scale.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>07/28/2021</MinAmdLetterDate>
<MaxAmdLetterDate>07/28/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>CoopAgrmnt</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2111884</AwardID>
<Investigator>
<FirstName>Marylaura</FirstName>
<LastName>Thomas</LastName>
<PI_MID_INIT>L</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Marylaura L Thomas</PI_FULL_NAME>
<EmailAddress>marylaura@gmail.com</EmailAddress>
<PI_PHON>4805770391</PI_PHON>
<NSF_ID>000776134</NSF_ID>
<StartDate>07/28/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>SEQUITUR HEALTH CORP</Name>
<CityName>SCOTTSDALE</CityName>
<ZipCode>852593558</ZipCode>
<PhoneNumber>4808185463</PhoneNumber>
<StreetAddress>12826 E Cibola Rd</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Arizona</StateName>
<StateCode>AZ</StateCode>
<CONGRESSDISTRICT>06</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>AZ06</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>080993323</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>SEQUITUR HEALTH CORP</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[SEQUITUR HEALTH CORP]]></Name>
<CityName>Scottsdale</CityName>
<StateCode>AZ</StateCode>
<ZipCode>852593558</ZipCode>
<StreetAddress><![CDATA[12826 E Cibola Rd.]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Arizona</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>06</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>AZ06</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>004E</Code>
<Text>BIOMEDICAL ENG AND DIAGNOSTICS</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~999101</FUND_OBLG>
</Award>
</rootTag>
